Sclerotherapy with or without octreotide for acute variceal bleeding

Area of Science:

• Gastroenterology
• Hepatology
• Interventional Endoscopy

Background:

• Esophageal varices pose a high risk of bleeding, rebleeding, and mortality despite sclerotherapy.
• Acute variceal bleeding necessitates effective management to prevent severe outcomes.

Purpose of the Study:

• To compare sclerotherapy alone versus sclerotherapy combined with octreotide for controlling acute variceal bleeding.
• To evaluate the efficacy of octreotide in preventing early rebleeding in patients with cirrhosis.

Main Methods:

• A double-blind, prospective trial involving 199 patients with cirrhosis and acute variceal bleeding.
• Patients received emergency sclerotherapy, followed by a continuous infusion of either octreotide (25 mcg/hr) or placebo for five days.
• The primary outcome was survival without rebleeding at five days post-sclerotherapy.

Main Results:

• The octreotide group showed a significantly higher survival rate without rebleeding (87%) compared to the placebo group (71%; P = 0.009).
• Patients receiving octreotide required fewer blood transfusions within 24 hours (1.2 units vs. 2.0 units; P = 0.006).
• Logistic regression identified treatment assignment and pre-treatment blood transfusion volume as independent predictors of survival without rebleeding.

Conclusions:

• Sclerotherapy combined with octreotide is more effective in controlling acute variceal bleeding than sclerotherapy alone.
• While octreotide improves outcomes regarding rebleeding, it does not significantly alter overall 15-day mortality rates.
• Side effects were minor and comparable between the octreotide and placebo groups.